158 related articles for article (PubMed ID: 25527049)
1. Co-acting gene networks predict TRAIL responsiveness of tumour cells with high accuracy.
O'Reilly P; Ortutay C; Gernon G; O'Connell E; Seoighe C; Boyce S; Serrano L; Szegezdi E
BMC Genomics; 2014 Dec; 15(1):1144. PubMed ID: 25527049
[TBL] [Abstract][Full Text] [Related]
2. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
3. A 71-gene signature of TRAIL sensitivity in cancer cells.
Chen JJ; Knudsen S; Mazin W; Dahlgaard J; Zhang B
Mol Cancer Ther; 2012 Jan; 11(1):34-44. PubMed ID: 22027696
[TBL] [Abstract][Full Text] [Related]
4. Differential susceptibility of gastric cancer cells to TRAIL-induced apoptosis.
Song NM; Jun S; Zang DY; Kim SG; Park HR; Kang D
Oncol Rep; 2013 Mar; 29(3):1224-30. PubMed ID: 23233033
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.
Tang X; Wu W; Sun SY; Wistuba II; Hong WK; Mao L
Mol Cancer Res; 2004 Dec; 2(12):685-91. PubMed ID: 15634757
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic analyses of the radiation response in head and neck squamous cell carcinoma subclones with different radiation sensitivity: time-course gene expression profiles and gene association networks.
Michna A; Schötz U; Selmansberger M; Zitzelsberger H; Lauber K; Unger K; Hess J
Radiat Oncol; 2016 Jul; 11():94. PubMed ID: 27455841
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas.
Heikaus S; Casliskan E; Mahotka C; Gabbert HE; Ramp U
Apoptosis; 2007 Sep; 12(9):1645-57. PubMed ID: 17610067
[TBL] [Abstract][Full Text] [Related]
8. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
9. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
[TBL] [Abstract][Full Text] [Related]
10. Identification of genes regulating TRAIL-induced apoptosis in rheumatoid arthritis fibroblasts-like synoviocytes.
Audo R; Hegglin A; Severac D; Dantec C; Combe B; Hahne M; Morel J
Genes Immun; 2015 Oct; 16(7):462-9. PubMed ID: 26247836
[TBL] [Abstract][Full Text] [Related]
11. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
12. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Patiño-García A; Zalacain M; Folio C; Zandueta C; Sierrasesúmaga L; San Julián M; Toledo G; De Las Rivas J; Lecanda F
Clin Cancer Res; 2009 Aug; 15(16):5082-91. PubMed ID: 19671856
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim K; Fisher MJ; Xu SQ; el-Deiry WS
Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508
[TBL] [Abstract][Full Text] [Related]
14. Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity.
O'Leary L; van der Sloot AM; Reis CR; Deegan S; Ryan AE; Dhami SP; Murillo LS; Cool RH; Correa de Sampaio P; Thompson K; Murphy G; Quax WJ; Serrano L; Samali A; Szegezdi E
Oncogene; 2016 Mar; 35(10):1261-70. PubMed ID: 26050621
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
Elias A; Siegelin MD; Steinmüller A; von Deimling A; Lass U; Korn B; Mueller W
Clin Cancer Res; 2009 Sep; 15(17):5457-65. PubMed ID: 19706813
[TBL] [Abstract][Full Text] [Related]
16. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma.
Azuhata T; Scott D; Griffith TS; Miller M; Sandler AD
J Pediatr Surg; 2006 Aug; 41(8):1431-40. PubMed ID: 16863850
[TBL] [Abstract][Full Text] [Related]
17. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death 4 (PDCD4) mediates the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by down-regulation of FLIP expression.
Wang W; Zhao J; Wang H; Sun Y; Peng Z; Zhou G; Fan L; Wang X; Yang S; Wang R; Fang D
Exp Cell Res; 2010 Sep; 316(15):2456-64. PubMed ID: 20595005
[TBL] [Abstract][Full Text] [Related]
19. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K
Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
